- Q1 2024 BioArctic AB Earnings Call TranscriptMay 17, 2024$21.7 (-1.05%)Earnings
- Q4 2023 BioArctic AB Earnings Call TranscriptFeb 14, 2024$19.03Earnings
- Q3 2023 BioArctic AB Earnings Call TranscriptNov 08, 2023$19.64 (-1.13%)Earnings
- Q2 2023 BioArctic AB Earnings Call TranscriptJul 12, 2023$27.16Earnings
- Q1 2023 BioArctic AB Earnings Call TranscriptApr 27, 2023$27.94Earnings
- Q4 2022 BioArctic AB Earnings Call TranscriptFeb 03, 2023$25.25Earnings
- Q3 2022 BioArctic AB Earnings Call TranscriptOct 20, 2022Earnings
- Q2 2022 BioArctic AB Earnings Call TranscriptJul 12, 2022Earnings
- Q1 2022 BioArctic AB Earnings Call TranscriptApr 28, 2022Earnings
- Q4 2021 BioArctic AB Earnings Call TranscriptFeb 03, 2022Earnings
- Q3 2021 BioArctic AB Earnings Call TranscriptOct 21, 2021Earnings
- Q2 2021 BioArctic AB Earnings Call TranscriptJul 09, 2021Earnings
- Q1 2021 BioArctic AB Earnings Call TranscriptApr 21, 2021Earnings
- Full Year 2020 BioArctic AB Earnings Call TranscriptFeb 04, 2021Earnings
- Nine Months 2020 BioArctic AB Earnings Call TranscriptOct 14, 2020Earnings
- Q2 2020 BioArctic AB Earnings Call TranscriptJul 10, 2020Earnings
- Q1 2020 BioArctic AB Earnings Call TranscriptApr 22, 2020Earnings
- Full Year 2019 BioArctic AB Earnings Call TranscriptFeb 06, 2020Earnings
- Q3 2019 BioArctic AB Earnings Call TranscriptOct 24, 2019Earnings
- Q2 2019 BioArctic AB Earnings Call TranscriptJul 11, 2019Earnings
- Q1 2019 BioArctic AB Earnings Call TranscriptMay 09, 2019Earnings
- Full Year 2018 BioArctic AB Earnings Call TranscriptFeb 14, 2019Earnings
Q4 2022 BioArctic AB Earnings Call Transcript
Welcome to BioArctic Q4 Report 2022. (Operator Instructions)
Now, I will hand the conference over to CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead.
()-
Thank you and Good morning and welcome to BioArctic presentation of the Fourth Quarter of 2022. I'm Gunilla Osswald, I am the CEO of BioArctic, and I will share today's presentation with our CFO, Jan Mattsson.
I will give an update on BioArctic, of course, and focus on the fantastic year we had last year and especially the fourth quarter with the groundbreaking results for lecanemab that was presented at the Alzheimer Congress CTAD in November in San Francisco with regard to the Phase III results. And I think it's really reassuring with some robust and consistent and positive Phase III results. This year has also started in a great way with an accelerated approval of lecanemab in the U.S. It's really exciting that lecanemab, or Leqembi, as it's named in the U.S. now it's available for patients in the U.S. and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)